Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin

2013 ◽  
Vol 28 (9) ◽  
pp. 1515-1520 ◽  
Author(s):  
Chung-Feng Huang ◽  
Ming-Lun Yeh ◽  
Meng-Hsuan Hsieh ◽  
Ming-Yen Hsieh ◽  
Zu-Yau Lin ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Clinical Utility ◽  
Pegylated Interferon ◽  
Genotype 1 ◽  
Virus Genotype ◽  
Asian Patients ◽  
Pegylated Interferon Plus Ribavirin ◽  
Host Genetic

scholarly journals Meta-Analysis: Superior Treatment Response in Asian Patients with Hepatitis C Virus Genotype 6 versus Genotype 1 with Pegylated Interferon and Ribavirin

Intervirology ◽  
2015 ◽  
Vol 58 (1) ◽  
pp. 27-34 ◽  
Author(s):  
Nghia H. Nguyen ◽  
Shelley A. McCormack ◽  
Philip Vutien ◽  
Brittany E. Yee ◽  
Pardha Devaki ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Treatment Response ◽  
Pegylated Interferon ◽  
Virologic Response ◽  
P Value ◽  
Genotype 1 ◽  
Virus Genotype ◽  
Asian Patients ◽  
Q Statistic

Objective: Our goal was to systematically and quantitatively assess treatment response between Asian patients with hepatitis C virus genotype 6 (HCV-6) and hepatitis C virus genotype 1 (HCV-1) treated for 48 weeks with pegylated interferon and ribavirin. Methods: We performed a literature search in MEDLINE and EMBASE for ‘genotype 6' in August 2013. Additional abstracts from major international scientific conferences from 2012 to 2013 were reviewed. Studies included were original articles with ≥10 treatment-naïve Asian HCV-6 patients. Exclusion criteria were coinfections with hepatitis B virus, HIV and/or other liver diseases. Heterogeneity was defined as a Cochrane Q test with a p value of 0.10 and an I2 statistic of >50%. Results of a random-effects model are reported. Results: A total of 1,046 (503 HCV-6; 543 HCV-1) patients from 12 studies were included in the analysis. The pooled sustained virologic response (SVR) rate was 80.2% (95% CI 74.3-85.0, Q statistic = 20.87, p < 0.035; I2 = 47.3%) for HCV-6 and 62.5% (95% CI 41.9-79.4, Q statistic = 52.41, p < 0.001; I2 = 92.37) for HCV-1 patients. HCV-6 patients had a significantly higher SVR rate compared to HCV-1 patients (odds ratio 2.73, 95% CI 1.69-4.41, p < 0.001). Approximately one fourth of patients without early virologic response (EVR) achieved SVR, regardless of genotype (HCV-1, n = 6/23; HCV-6, n = 4/21). Conclusions: Asian patients with HCV-6 can expect higher SVR rates (∼80%) than HCV-1 patients (∼63%). EVR as a stopping rule is less clear in Asian patients with HCV-6 and HCV-1.

scholarly journals Effectiveness of sofosbuvir/pegylated-interferon plus ribavirin in treatment of hepatitis C virus genotype 4 patients

2018 ◽  
Vol 4 (3) ◽  
pp. 191-196 ◽  
Author(s):  
Abel Abdel-Moneim ◽  
Alaa Abood ◽  
Mohamed Abdel-Gabaar ◽  
Mohamed I. Zanaty ◽  
Mohamed Ramadan
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Pegylated Interferon ◽  
Virus Genotype ◽  
Genotype 4 ◽  
Pegylated Interferon Plus Ribavirin

scholarly journals Long-term Pegylated Interferon Monotherapy Following 72 Weeks of Pegylated Interferon and Ribavirin in Hepatitis C Virus Genotype-1-infected Slow Responders

2015 ◽  
Vol 54 (3) ◽  
pp. 273-279 ◽  
Author(s):  
Shinya Watanabe ◽  
Yoshimasa Kobayashi ◽  
Kazuhito Kawata ◽  
Hidenao Noritake ◽  
Takeshi Chida ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Pegylated Interferon ◽  
Genotype 1 ◽  
Virus Genotype ◽  
Interferon Monotherapy

scholarly journals Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis

2017 ◽  
Vol 25 (1) ◽  
Author(s):  
Fardin Dolatimehr ◽  
Hamidreza Karimi-Sari ◽  
Mohammad Saeid Rezaee-Zavareh ◽  
Seyed Moayed Alavian ◽  
Bita Behnava ◽  
...  
Keyword(s):  
Systematic Review ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Meta Analysis ◽  
Pegylated Interferon ◽  
Genotype 1 ◽  
Virus Genotype

Clinical efficacy of combination therapy with ME3738 and pegylated interferon-alpha-2a in patients with hepatitis C virus genotype 1

2013 ◽  
Vol 44 (4) ◽  
pp. 410-419 ◽  
Author(s):  
Toshiji Saibara ◽  
Nobuyuki Enomoto ◽  
Shuichi Kaneko ◽  
Kazuaki Chayama ◽  
Michio Sata ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Combination Therapy ◽  
Interferon Alpha ◽  
Clinical Efficacy ◽  
Pegylated Interferon ◽  
Genotype 1 ◽  
Virus Genotype ◽  
Pegylated Interferon Alpha
Sign in / Sign up

Export Citation Format

Share Document